BioSpace News Archive

Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.

Friday, the Supreme Court granted the FDA’s application for a stay, effectively maintaining access to the abortion pill mifepristone as its case goes through the appeals process.

To give the FDA more time to evaluate updates to quizartinib’s proposed REMS program, the regulator is pushing the target action date to July 24.

Amphastar Pharmaceuticals, Inc. announced that the Company will provide a Business update and hold a Conference call , Monday, April 24, 2023, at 6:00 am Pacific Time.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3rd ISIET’s International Symposium on Inner Ear Therapeutics, an event sponsored by Sensorion, taking place on April 28-30, 2023, in Marrakech, Morocco.

Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023.

Medigene AG reports final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell therapy for high-risk myeloid and lymphoid neoplasms.

Theravance Biopharma, Inc. will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.